» Articles » PMID: 16773269

Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy Assessed by MRI

Overview
Journal J Neurol
Specialty Neurology
Date 2006 Jun 15
PMID 16773269
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Using MRI, we evaluated the degree of involvement of muscles in the lower extremities of 18 unselected patients with facioscapulohumeral muscular dystrophy (FSHD). Findings were correlated with fragment size of the mutated gene, age, disease duration and muscle power. Most affected muscles were the hamstrings followed by the tibialis anterior and the medial gastrocnemius. The vastus-, gluteal- and peroneal muscles were the most unaffected, and the psoas muscle did not show evidence of involvement in any of the investigated subjects. Asymmetric involvement was evident in 15% of the investigated muscles on MRI and 6% on manual muscle strength testing. MRI findings in muscle tended to correlate with disease duration (r = 0.49; p < 0.05), but not with gene fragment size or age. MRI disclosed involvement of muscles performing hip flexion and ankle dorsal flexion that could not be detected by manual muscle strength testing. Otherwise, there was a close correlation (approximately r = 0.75; p < 0.0001) between muscle strength and MRI severity score for other muscle groups. The present study shows that MRI may disclose muscle involvement in FSHD that is not apparent on manual muscle testing, and suggests that MRI of muscle may be an important assessment tool in clinical trials involving patients with FSHD.

Citing Articles

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.

Arends T, Hamm D, van der Maarel S, Tapscott S Cold Spring Harb Perspect Biol. 2024; .

PMID: 39009417 PMC: 11733064. DOI: 10.1101/cshperspect.a041492.


The DUX4-HIF1α Axis in Murine and Human Muscle Cells: A Link More Complex Than Expected.

Nguyen T, Limpens M, Bouhmidi S, Paprzycki L, Legrand A, Decleves A Int J Mol Sci. 2024; 25(6).

PMID: 38542301 PMC: 10969790. DOI: 10.3390/ijms25063327.


Facioscapulohumeral muscular dystrophy: the road to targeted therapies.

Tihaya M, Mul K, Balog J, de Greef J, Tapscott S, Tawil R Nat Rev Neurol. 2023; 19(2):91-108.

PMID: 36627512 PMC: 11578282. DOI: 10.1038/s41582-022-00762-2.


Management of scapular dysfunction in facioscapulohumeral muscular dystrophy: the biomechanics of winging, arthrodesis indications, techniques and outcomes.

Eren I, Gedik C, Kilic U, Abay B, Birsel O, Demirhan M EFORT Open Rev. 2022; 7(11):734-746.

PMID: 36475552 PMC: 9780611. DOI: 10.1530/EOR-22-0080.


Whole-muscle fat analysis identifies distal muscle end as disease initiation site in facioscapulohumeral muscular dystrophy.

Heskamp L, Ogier A, Bendahan D, Heerschap A Commun Med (Lond). 2022; 2(1):155.

PMID: 36450865 PMC: 9712512. DOI: 10.1038/s43856-022-00217-1.


References
1.
Upadhyaya M, Cooper D . Molecular diagnosis of facioscapulohumeral muscular dystrophy. Expert Rev Mol Diagn. 2002; 2(2):160-71. DOI: 10.1586/14737159.2.2.160. View

2.
Kissel J . Facioscapulohumeral dystrophy. Semin Neurol. 2000; 19(1):35-43. DOI: 10.1055/s-2008-1040824. View

3.
Phoenix J, Betal D, Roberts N, Helliwell T, EDWARDS R . Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve. 1996; 19(3):302-10. DOI: 10.1002/(SICI)1097-4598(199603)19:3<302::AID-MUS4>3.0.CO;2-H. View

4.
Kilmer D, Abresch R, McCrory M, Carter G, FOWLER Jr W, Johnson E . Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil. 1995; 74(5 Suppl):S131-9. DOI: 10.1097/00002060-199509001-00007. View

5.
Tawil R, Figlewicz D, Griggs R, Weiffenbach B . Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Ann Neurol. 1998; 43(3):279-82. DOI: 10.1002/ana.410430303. View